BioCentury
ARTICLE | Company News

CoCensys, Warner-Lambert deal

October 27, 1997 8:00 AM UTC

The partners extended for two years their 1995 collaboration to discover sub-type specific NMDA receptor antagonists that block glutamate neurotransmitter activity, and will include the discovery of compounds that modulate activity of AMPA glutamate receptors. The collaboration will focus on stroke, Parkinson's disease, pain, schizophrenia and epilepsy.

Under the expanded agreement, Warner-Lambert will make a $7 million equity investment in COCN, and could pay up to $16.5 million in milestone payments, plus royalties. COCN also will retain an option to participate in commercialization of resulting compounds. The companies will share R&D costs. ...